A Phase 3 interventional study of Rotigotine in Early Stage Parkinson's Disease, sponsored by UCB Pharma. Completed at 63 sites in 20 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 5th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2002, is one of 20 in phase 3, and was the 16th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 3 started in 2002.
This study's enrollment of 381 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 6th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2002, is one of 19 in phase 3, and was the 17th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
This is the open-label extension to the randomized, double-blind, placebo- and ropinirole-controlled SP513 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with early-stage idiopathic Parkinson's Disease
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rotigotine
Drug: Rotigotine
Rotigotine trans-dermal patches, once daily: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours); Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours. After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours.
Also known as: Neupro®
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: six years
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
Time frame: six years
Mean Epworth Sleepiness Scale Score During the Open-label Extension
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.
Time frame: Visit 10 (end of year 1), Visit 14 (end of year 2), Visit 18 (end of year 3), Visit 22 (end of year 4), Visit 26 (end of year 5), Visit 30 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
An Open-Label Extension to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects with Early-Stage Idiopathic Parkinson's Disease from August 2002 to December 2008
| Milestone | Rotigotine |
|---|---|
| Started | 381 |
| Completed | 0 |
| Not completed | 381 |
| Withdrew: Lack of efficacy | 22 |
| Withdrew: Adverse event | 93 |
| Withdrew: Unsatisfactory compliance of subject | 3 |
| Withdrew: Subject withdrew consent | 43 |
| Withdrew: Study ended per sponsor | 197 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Other: patient leaving for israel | 1 |
| Withdrew: Other: spouse withdrew consent | 1 |
| Withdrew: Other: diagnosis no longer idiopathic pd | 1 |
| Withdrew: Other: pt moved to australia | 1 |
| Withdrew: Other: patient stopped due to moving | 1 |
| Withdrew: Other: inv switched dopamine agonist | 1 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| Subjects | Rotigotine |
|---|---|
| Number of Subjects With at Least One Adverse Event During This Open-label Extension Study | 369 |
Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.
| Subjects | Rotigotine |
|---|---|
| Number of Subjects Who Withdrew From the Trial Due to an Adverse Event | 93 |
The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.
| Score on a scale | Rotigotine |
|---|---|
| Visit 10 (end of year 1) (n=375) | 5.8 ± 3.8 |
| Visit 14 (end of year 2) (n=375) | 6.2 ± 4.1 |
| Visit 18 (end of year 3) (n=375) | 6.7 ± 4.5 |
| Visit 22 (end of year 4) (n=375) | 6.7 ± 4.6 |
| Visit 26 (end of year 5) (n=375) | 6.7 ± 4.5 |
| Visit 30 (end of year 6) (n=375) | 6.8 ± 4.5 |
| End of Treatment (n=377) | 6.8 ± 4.5 |
Collected over up to 6 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 131/380 (34.5%) | 323/380 (85%) |
| Event | Rotigotine |
|---|---|
| OsteoarthritisMusculoskeletal and connective tissue disorders | 11/380 |
| Myocardial infarctionCardiac disorders | 10/380 |
| FallInjury, poisoning and procedural complications | 9/380 |
| Parkinson's diseaseNervous system disorders | 9/380 |
| Femoral neck fractureInjury, poisoning and procedural complications | 6/380 |
| CholelithiasisHepatobiliary disorders | 5/380 |
| Femur fractureInjury, poisoning and procedural complications | 5/380 |
| PneumoniaInfections and infestations | 4/380 |
| HallucinationPsychiatric disorders | 4/380 |
| Inguinal herniaGastrointestinal disorders | 3/380 |
| Event | Rotigotine |
|---|---|
| SomnolenceNervous system disorders | 146/380 |
| NauseaGastrointestinal disorders | 72/380 |
| Oedema peripheralGeneral disorders | 71/380 |
| Back painMusculoskeletal and connective tissue disorders | 57/380 |
| DizzinessNervous system disorders | 51/380 |
| InsomniaPsychiatric disorders | 48/380 |
| Application site reactionGeneral disorders | 45/380 |
| FallInjury, poisoning and procedural complications | 43/380 |
| HypertensionVascular disorders | 41/380 |
| DepressionPsychiatric disorders | 38/380 |
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 215 |
| >=65 years | 165 |
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 61.6 ± 10.0 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 150 |
| Male | 230 |
| Region of Enrollment(participants) | Rotigotine |
|---|---|
| Finland | 16 |
| Spain | 10 |
| Austria | 12 |
| Israel | 30 |
| United Kingdom | 38 |
| Italy | 9 |
| Switzerland | 4 |
| France | 10 |
| Czech Republic | 44 |
| Hungary | 17 |
| Poland | 65 |
| Belgium | 12 |
| Croatia | 17 |
| Australia | 7 |
| South Africa | 42 |
| Germany | 7 |
| Norway | 4 |
| Netherlands | 5 |
| New Zealand | 19 |
| Sweden | 12 |
The record gives a start of Aug 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine